6Melegari M,Scaglioni PP,Wards JR.Hepatitis B virus mutants associated with 3TC and famiciclovir administration are replicaion defective[J].Hepatology,1998,27:628-633
7Chayama K,Suzuki Y,Kobayashi M,et al.Emergence and ta-keover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wide type after cessation of therapy[J].Hepatology,1998,27:1711-1716
8Liaw YF,Leung NW,Chang TT,et al.Effects of extended lamivudine therpy in asian patients with chronic hepatitis B[J].Gastroenterology,2000,119:172-180
9Liaw YF.Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B[J].Antiviral Chem Chemother,2001,12(suppll):67-71
3[4]Stange T , Hassanein TI , Mehta R, et al. The molecular absorbyling system as a liver support systrm based on albumin dialysis: a summary of preclinical investigations, prospective, randomizd ,controlled clinical trial and clinical experience from 19 centers.Artif Organs ,2002,26:103～110
5Maria Buti,Rafael Esteban.Entecavir, FTC, L-RMAU, LdT and others[].Journal of Hepatology.2003
6Fontana RJ.Mangement of patients with decompensated HBV cirrhosis[].Seminars in Liver Disease.2003
7Hom X,Little NR,Gardner SD,et al.Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection[].Pediatric Infectious Disease.2004
8Kobayashi S,Ide T,Sata M,et al.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers[].Journal of Hepatology.2001
9Li LL,Chun TW,Yin ML,et al.Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy[].Hepatology.2000
10Liaw YF,Sung JJY,Chow WC,et al.Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial[].Hepatology.2003
